Obesity

Generic semaglutide surge dents Mounjaro sales, reshaping India's fast-growing GLP-1 diabetes and obesity drug market

Emcure cuts Poviztra prices by up to 55% following Novo Nordisk's move, lowering monthly treatment costs for semaglutide-based obesity therapy in India

Prime Minister Narendra Modi on Sunday urged citizens to reduce their sugar intake and cut down on cooking oil by 10 per cent, saying such small efforts will keep people away from obesity and lifestyle diseases. In his monthly radio address, 'Mann Ki Baat', Modi said many people have commented on Instagram content creator Yuvraj Dua's post, in which he had requested the prime minister to ask his father to reduce his sugar intake. "I am happy that my request had a positive impact on his father. I would urge all of you to reduce your sugar intake, and as I have said earlier, we also need to cut down on cooking oil by 10 per cent. These small efforts will keep you away from obesity and lifestyle diseases," Modi said. The prime minister said he has always urged everyone to pay attention to fitness. "Now, less than 100 days are left for International Yoga Day; the attraction towards yoga is also rising continuously all over the world. Almis Ji is promoting yoga through his Arvind Yoga .

According to the National Family Health Survey 2019-21, 24 per cent of Indian women and 23 per cent of Indian men are overweight

As cheaper GLP-1 weight-loss drugs flood India after patent expiry, the government has intensified surveillance to curb illegal sales, misleading promotion, and unsafe use without medical supervision

As semaglutide goes off patent, doctors warn of misuse by non-obese individuals amid rising demand driven by social media and lower-cost generics

Novo Nordisk says competition in semaglutide will be driven by science and quality, not pricing, as multiple generic versions prepare to enter India after patent expiry

A Lancet report warns counterfeit weight-loss injections like Ozempic and Mounjaro are spreading globally, driven by high demand and prices, raising serious risks for patients

India is the first major country after Canada where Novo is losing patent on semaglutide and will see an onslaught of generic versions

Body weight is biologically regulated, and targeting the right biological pathways can lead to meaningful weight loss that can help transform lives

Drug regulator warns pharma companies that obesity awareness drives linked to GLP-1 drugs could amount to misleading promotion of prescription medicines

Obesity surgery services were formally launched on Monday at Maharaja Yashwantrao Hospital (MYH) in Indore, making it the first such facility in the government healthcare sector in Madhya Pradesh, an official said. Obesity has emerged as a serious social problem, leading to ailments such as diabetes and high blood pressure, divisional commissioner (revenue) Sudam Khade said while inaugurating the bariatric clinic in the surgery department of MYH. "Keeping this in view, bariatric surgery services have been started at MYH. This is the first such facility of its kind in the state's government sector. Patients holding Ayushman cards will be able to avail the facility free of cost, while obesity reduction surgery in private hospitals generally costs between Rs 4-5 lakh," Khade said. Gul Afshan (30), who underwent bariatric surgery at MYH, said her weight reduced from 120 kg to 97 kg within one-and-a-half months after the operation. "This has provided relief from my diabetes problem and

Peter ter Kulve, CEO of Magnum Ice Cream, said GLP-1 users continue to eat treats, but they exhibit "a stark reduction of mindless munching and binge eating"

The company ​last month received an approval from ‌India's drug regulator ​to manufacture ‌and sell the generic version ‌of blockbuster diabetes drug Ozempic

A major Lancet study finds adults with obesity are far more likely to be hospitalised or die from infections, linking nearly one in 10 infection deaths worldwide to excess weight

A nationwide LocalCircles survey shows obesity is no longer an individual issue, with most Indians reporting obese family members or friends, underscoring India's growing public health challenge

India has entered the first phase of generic semaglutide approvals, with CDSCO clearing multiple formulations for obesity and diabetes, paving the way for lower-cost GLP-1 therapies

Endocrinologist explains how to build a realistic weight-loss plan that can help you lose fat without regaining it

Many people regain weight after stopping Ozempic and similar drugs. Expert shares why it happens and the practical steps needed to maintain weight in the long term

Here's how homeostasis, hormones and obesity drugs affect why lost weight often returns faster than expected